- Home
- FNLC vs ALDX Comparison
FNLC vs ALDX Comparison
Compare FNLC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- ALDX
- Stock Information
- Founded
- FNLC 1864
- ALDX 2004
- Country
- FNLC United States
- ALDX United States
- Employees
- FNLC N/A
- ALDX N/A
- Industry
- FNLC Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- ALDX Health Care
- Exchange
- FNLC Nasdaq
- ALDX Nasdaq
- Market Cap
- FNLC 303.4M
- ALDX 314.6M
- IPO Year
- FNLC 1999
- ALDX 2014
- Fundamental
- Price
- FNLC $24.98
- ALDX $4.85
- Analyst Decision
- FNLC
- ALDX Strong Buy
- Analyst Count
- FNLC 0
- ALDX 2
- Target Price
- FNLC N/A
- ALDX $9.50
- AVG Volume (30 Days)
- FNLC 22.1K
- ALDX 644.4K
- Earning Date
- FNLC 10-22-2025
- ALDX 11-06-2025
- Dividend Yield
- FNLC 5.84%
- ALDX N/A
- EPS Growth
- FNLC 18.07
- ALDX N/A
- EPS
- FNLC 2.81
- ALDX N/A
- Revenue
- FNLC $88,119,000.00
- ALDX N/A
- Revenue This Year
- FNLC N/A
- ALDX N/A
- Revenue Next Year
- FNLC N/A
- ALDX $63.48
- P/E Ratio
- FNLC $8.85
- ALDX N/A
- Revenue Growth
- FNLC 12.70
- ALDX N/A
- 52 Week Low
- FNLC $22.11
- ALDX $1.14
- 52 Week High
- FNLC $31.05
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- FNLC 46.53
- ALDX 40.65
- Support Level
- FNLC $24.39
- ALDX $4.84
- Resistance Level
- FNLC $25.46
- ALDX $5.27
- Average True Range (ATR)
- FNLC 0.43
- ALDX 0.26
- MACD
- FNLC 0.06
- ALDX -0.04
- Stochastic Oscillator
- FNLC 40.13
- ALDX 26.23
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.